SkinBio said Stuart John Ashman’s appointment would allow him to gain an understanding of the business while incumbent CEO Dr Cath O’Neill would focus on the company’s scientific developments and ongoing commercial discussions
Newswires
Showing 25 of 6166
"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO
Full-year results are due out next month, and Mediclinic expects underlying earnings to fall by 3.5%, although analysts had thought they might tumble by as much as 4.8%
Moataz Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems, the world's largest manufacturer of radiotherapy equipment for 12 years
The presentation provided a drill-down in the results from the company’s REVIVE study
Giles Campion has been appointed head of research and development and chief medical officer
The total of US$109mln is more than Autolus had originally set out to raise from the market
Securing approval in the US for iclaprim remains the top priority for Motif Bio, the company said as it posted full-year 2018 results which saw losses narrow sharply
The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs
Plenity has been cleared for the BMI 25-40 kg/M2 category, the widest category of adults suffering from obesity
The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group
Autolus said earlier this week it was looking to raise money from investors, and it has today confirmed plans to raise US$100.8mln through the issue of 4.2mln shares at US$24 each
A new management team came in last year, and hVIVO expects the changes it implemented to start to bear fruit this year before the benefits really kick in next year
Faron has recruited four people to its trial, and although all of them have reacted well to the drug so far, the colorectal cancer patient has seen the most dramatic response
Xonvea will be prescribed to women who are sick during pregnancy where conservative treatment has failed
"We are pleased with our delivery of high double-digit growth within our core business representing a substantial turn-around of performance from our prior financial year,” chief executive Jamal Rushdy
The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells
The partner company, which was not named, had “an established track record” of taking new products to pharmacies and wholesalers via its distribution network in the country
The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering
It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
Recovering drug addicts who were treated with higher doses of Sublocade were more likely to remain drug-free for longer than those on the lower dose
MyLotus was recently launched in the UK and Concepta now wants to launch the fertility testing kit in international territories
Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance
Indivior’s chief scientific officer, Christian Heidbreder commented: "RECOVER is assessing real-world outcomes in patients for up to two years after they completed our clinical phase 3 Sublocade study"
Several ANGLE customers have been showcasing Parsortix at the American Association for Cancer Research conference in Atlanta
